DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

As a leading CGM maker, DexCom is likely to play a significant role in diabetes care for years, possibly decades. Given all ...

These once-sizable artificial intelligence (AI) holdings for Google parent Alphabet have been paired down big-time over the ...

DexCom (NASDAQ: DXCM ... and that was one of the biggest reasons to avoid it. But due to the sharp sell-off this year, it's now priced at a much more tenable valuation. And not only is the ...

This is why Insulet has integrated its system with the glucose monitoring devices made by both Abbott and Dexcom — which is something that Tandem has done as well. “This type of collaboration ...

Both Dexcom and Abbott were recently approved to sell over-the-counter CGMs that are targeted towards Type 2 diabetes, or people not required to take insulin. It is a much larger universe of ...

We believe integration with iOS smartphones and the latest CGMs from Dexcom and Abbott should help ... customer service and relationship goals. We sell different types of products and services ...

Stock indexes may have rallied higher since bottoming in August. But, some stocks have fallen behind, and are looking to ...

These top holdings include companies like Dexcom Inc., Datadog Inc. (Class A Shares), IDEXX ... this ETF allows investors to easily buy and sell shares like traditional stocks, making it a convenient ...

Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...

DexCom (NASDAQ: DXCM) is a big name in diabetes care. Its continuous glucose monitors (CGMs) help people track their blood glucose levels. But the stock has been performing poorly this year amid ...